Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Mylan Joins With Biocon In Biogenerics

by Ann M. Thayer
July 6, 2009 | A version of this story appeared in Volume 87, Issue 27

Generic drug company Mylan will share costs and work with the Indian biotechnology firm Biocon to develop, make, and sell generic biologic compounds for the global market. Mylan will have exclusive commercial rights in most of the developed world but will split profits with Biocon. In other markets, the companies will share commercial rights. “Generic biologics, especially monoclonal antibodies, are expected to become the next great bolus of growth in the generic pharmaceutical industry,” Mylan CEO Robert J. Coury says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.